Frexalimab for nephrosis, lipoid

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 15 Jul 2024: Trial registered, NCT06500702
  2. 19 Dec 2024: Trial started, NCT06500702

The trials

NCT06500702: A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease

State
Under way
Phase
Phase 2
People
84 planned
Started
19 Dec 2024
Primary completion
23 Dec 2026
Arms
Frexalimab
Results
None posted
  1. 15 Jul 2024: Trial registered
  2. 19 Dec 2024: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.